25 years of biologic DMARDs in rheumatology

2023 marks 25 years since the approval of the first biologic drug in rheumatology. In this Viewpoint, five rheumatology researchers discuss how biologic therapy has transformed clinical practice, reflecting on their own experience, past and current challenges and what the future might hold for biolo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Rheumatology 2023-12, Vol.19 (12), p.761-766
Hauptverfasser:	Feldmann, Marc, Maini, Ravinder N., Soriano, Enrique R., Strand, Vibeke, Takeuchi, Tsutomu
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4023 692/700/565/1331 Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological products Biological Products - therapeutic use Clinical medicine Clinical trials Cytokines Drugs Humans Medical research Medicine Medicine & Public Health Monoclonal antibodies Psoriatic arthritis Quality of life Rheumatic diseases Rheumatoid arthritis Rheumatology Success TNF inhibitors Viewpoint
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	2023 marks 25 years since the approval of the first biologic drug in rheumatology. In this Viewpoint, five rheumatology researchers discuss how biologic therapy has transformed clinical practice, reflecting on their own experience, past and current challenges and what the future might hold for biologic drugs.
ISSN:	1759-4790 1759-4804
DOI:	10.1038/s41584-023-01036-x